OMAHA - Thekisselkohoutes.com/news University of Nebraska Medical Center and Nebraska Medicine have launched a new clinical research trial to evaluate the effectiveness of an oral drug that could prevent COVID-19.

The trial will reportedly evaluate the drug Molnupiravir which is sponsored by Merck Sharp & Dohme Corp.

The trial is randomized, double-blind and placebo-controlled. Adult participants will be used to evaluate the safety and effectiveness of Molnupiravir, specifically whether it prevents hospitalization or death in adults who are living with a person who has COVID-19.

For 12 hours a day for five days, participants will randomly receive either the drug or the placebo and be asked to follow-up over the course of the next 30 days.

The study plans to research the effectiveness and safety of the medication in over 1,300 international participants.

Those who qualify for the study must be at least 19 years of age, have not gotten a COVID-19 vaccine, have never had COVID-19, and live with someone who recently tested positive for COVID-19.

For the full article click HERE